Biologically Active Small Molecules

A derivative of testosterone and ethisterone that binds androgen receptors and sex hormone-binding globulin causing a 3-fold increase in free testosterone possesses weak androgenic effects and inhibits the production of gonadotropins.

A derivative of testosterone and ethisterone that binds androgen receptors and sex hormone-binding globulin causing a 3-fold increase in free testosterone possesses weak androgenic effects and inhibits the production of gonadotropins.

A skeletal muscle relaxant that depresses excitation-contraction coupling in skeletal muscle by binding to the type 1 ryanodine receptor and decreasing free intracellular calcium concentration inhibits L-type currents in developing myotubes by

A skeletal muscle relaxant that depresses excitation-contraction coupling in skeletal muscle by binding to the type 1 ryanodine receptor and decreasing free intracellular calcium concentration inhibits L-type currents in developing myotubes by

A skeletal muscle relaxant that depresses excitation-contraction coupling in skeletal muscle by binding to the type 1 ryanodine receptor and decreasing free intracellular calcium concentration inhibits L-type currents in developing myotubes by

Danusertib is a pan-Aurora kinase inhibitor (IC₅₀s = 13, 79, and 61 nM for Aurora A, B, and C, respectively) that also targets Abl, Ret, TrkA and FGFR1 (IC₅₀s = 25, 31, 31, and 47 nM, respectively). It exhibits

Danusertib is a pan-Aurora kinase inhibitor (IC₅₀s = 13, 79, and 61 nM for Aurora A, B, and C, respectively) that also targets Abl, Ret, TrkA and FGFR1 (IC₅₀s = 25, 31, 31, and 47 nM, respectively). It exhibits

Danusertib is a pan-Aurora kinase inhibitor (IC₅₀s = 13, 79, and 61 nM for Aurora A, B, and C, respectively) that also targets Abl, Ret, TrkA and FGFR1 (IC₅₀s = 25, 31, 31, and 47 nM, respectively). It exhibits

Danusertib is a pan-Aurora kinase inhibitor (IC₅₀s = 13, 79, and 61 nM for Aurora A, B, and C, respectively) that also targets Abl, Ret, TrkA and FGFR1 (IC₅₀s = 25, 31, 31, and 47 nM, respectively). It exhibits

A first generation, selective SGLT inhibitor that blocks glucose transport with about 100-fold selectivity for SGLT2 (Ki = 6 nM EC50 = 1.1 nM) over SGLT1 (Ki = 390 nM) 0.

A first generation, selective SGLT inhibitor that blocks glucose transport with about 100-fold selectivity for SGLT2 (Ki = 6 nM EC50 = 1.1 nM) over SGLT1 (Ki = 390 nM) 0.

A first generation, selective SGLT inhibitor that blocks glucose transport with about 100-fold selectivity for SGLT2 (Ki = 6 nM EC50 = 1.1 nM) over SGLT1 (Ki = 390 nM) 0.